Soares JC
Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA.
ArticlePsilocybin
Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.
ArticlePsilocybin
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.
ArticlePsilocybin
Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine.
ArticlePsilocybin
Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?
ArticleKetamine
Peripartum Depression Pharmacotherapies Targeting GABA-Glutamate Neurotransmission.
ArticlePsilocybin
Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
ArticleKetamine
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
ArticlePsilocybin
Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?
ArticlePsilocybin
Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.
ArticlePsilocybin
Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin.
ArticleKetamine
New agents and perspectives in the pharmacological treatment of major depressive disorder.
ArticleAyahuasca